Capital Research Global Investors Invests $47.70 Million in ADMA Biologics Inc $ADMA

Capital Research Global Investors bought a new stake in ADMA Biologics Inc (NASDAQ:ADMA) in the 3rd quarter, Holdings Channel.com reports. The fund bought 3,253,913 shares of the biotechnology company’s stock, valued at approximately $47,702,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vestcor Inc boosted its position in ADMA Biologics by 68.7% in the 3rd quarter. Vestcor Inc now owns 48,122 shares of the biotechnology company’s stock valued at $705,000 after buying an additional 19,593 shares during the period. Fieldview Capital Management LLC acquired a new stake in ADMA Biologics during the 3rd quarter worth $296,000. Swiss National Bank increased its position in ADMA Biologics by 1.9% during the third quarter. Swiss National Bank now owns 462,800 shares of the biotechnology company’s stock worth $6,785,000 after buying an additional 8,800 shares during the period. Neo Ivy Capital Management acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $130,000. Finally, Dimensional Fund Advisors LP increased its position in ADMA Biologics by 0.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock valued at $70,343,000 after acquiring an additional 35,199 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 4.3%

NASDAQ:ADMA opened at $14.99 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics Inc has a one year low of $13.76 and a one year high of $25.67. The stock has a 50-day simple moving average of $16.69 and a 200 day simple moving average of $16.72. The company has a market capitalization of $3.57 billion, a price-to-earnings ratio of 24.98 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. During the same period in the prior year, the company earned $0.46 earnings per share. The firm’s revenue was up 18.4% compared to the same quarter last year. Sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.00.

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms bought 7,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was purchased at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the transaction, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is owned by company insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.